Triazenes pp 15-22 | Cite as

Mechanisms of the Biological Actions of Triazenes

  • M. J. Tisdale


5-(3,3-Dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC, Fig. 1) was the first member of the series of antitumour triazenes and was chosen for clinical trial because of its activity against murine leukaemia L1210. Significant activity was demonstrated against malignant melanoma with an overall response rate of 21%, while marginal activity was demonstrated against other solid tumours.


Antitumour Activity Human Leukaemia Cell Line Haemoglobin Synthesis Antitumour Agent L1210 Leukaemia Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S.K. Carter and M.A. Friedman, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388) A new antitumour agent with activity against malignant melanoma, Eur. J. Cancer 8:85 (1972).PubMedCrossRefGoogle Scholar
  2. 2.
    A.H. Girculath and T.L. Loo, Mechanism of action of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide in mammalian cells in culture, Biochem. Pharmacol. 21:2335 (1972).CrossRefGoogle Scholar
  3. 3.
    H.T. Nagasawa, F.N. Shirota and N.S. Mizuno, The mechanism of alkylation of DNA by 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MIC), a metabolite of DIC (NSC-45388). Non-involvement of diazomethane, Chem.-Biol. Interactions, 8: 403 (1974).CrossRefGoogle Scholar
  4. 4.
    G.F. Kolar, M. Maurer and M. Wildschütte, 5-(3-Hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide (DIC, DTIC, NSC-45388) Cancer Lett. 10:235 (1980).PubMedCrossRefGoogle Scholar
  5. 5.
    L. Meer, R.C. Janzer, P. Kleihues and G.F. Kolar, In vivo metabolism and reaction with DNA of the cytostatic agent, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC), Biochem. Pharmacol. 35:3243 (1986).PubMedCrossRefGoogle Scholar
  6. 6.
    R.C.S. Audette, T.A. Connors, H.G. Mandel, K. Merai and W.C.J. Ross, Studies on the mechanism of action of the tumour inhibitory triazenes, Biochem. Pharmacol. 22:1855 (1973).PubMedCrossRefGoogle Scholar
  7. 7.
    P.D. Lawley, DNA as a target of alkylating carcinogens, Brit. Med. Bull. 36:1 (1980).Google Scholar
  8. 8.
    T.A. Connors, P.M. Goddard, K. Merai, W.C.J. Ross and D.E.V. Wilman, Tumour inhibitory triazenes; structural requirements for an active metabolite, Biochem. Pharmacol. 25:241 (1976).PubMedCrossRefGoogle Scholar
  9. 9.
    A. Gescher, J.A. Hickman, R.J, Simmonds, M.F.G. Stevens and K. Vaughan, Studies on the mode of action of antitumour triazenes and triazines — II. Investigation of the selective toxicity of 1-aryl-3,3-dimethyltriazenes, Biochem. Pharmacol. 30:89 (1981).PubMedCrossRefGoogle Scholar
  10. 10.
    G. Sava, S. Zorzet, L. Perissin, T. Giraldi and L. Lassiani, Effects of an inducer and an inhibitor of hepatic metabolism on the antitumour action of dimethyltriazenes, Cancer Chemother. Pharmacol. 21:241 (1988).PubMedCrossRefGoogle Scholar
  11. 11.
    V.H. Bono, Jr., Studies on the mechanism of action of DTIC (NSC-45388), Cancer Treat. Rep. 60:141 (1976).PubMedGoogle Scholar
  12. 12.
    N.W. Gibson, J. Hartley, R.J. LaFrance and K. Vaughan, Diferential cytotoxicity and DNA-damaging effects produced in human cells of the Mer+ and Mer- phenotypes by a series of alkyltriazenylimidazoles, Carcinogenesis 7:259 (1980).CrossRefGoogle Scholar
  13. 13.
    J.M. Lunn and A.L. Harris, Cytotoxicity of 5-(3-methyl-1-triazeno)-imidazole-4-carboxamide (MTIC on Mer+, Mer+Rem- and Mer- cell lines; Differential potentiation by 3-acetamidobenzamide, Br. J. Cancer 57:54 (1988).PubMedCrossRefGoogle Scholar
  14. 14.
    J.A. Hickman, M.F.G. Stevens, N.W. Gibson, S.P. Langdon, C. Fizames, F. Lavelle, G. Atassi, E. Lunt and R.M. Tilson, Experimental antitumour activity against murine tumour model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (Mitozolomide), a novel broad-spectrum agent. Cancer Res., 45:3008 (1985).PubMedGoogle Scholar
  15. 15.
    M.F.G. Stevens, J.A. Hickman, S.P. Langdon, D. Chubb, L. Vickers, R. Stone, G. Baig, C. Goddard, N.W. Gibson, J.A. Slack, C. Newton, E. Lunt, C. Fizames and F. Lavelle, Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M and B 39831), a novel drug with potential as an alternative to dacarbazine, Cancer Res. 47: 5846 (1987).PubMedGoogle Scholar
  16. 16.
    O. Fodstad, S. Aamdal, A. Pihl and M.R. Boyd, Activity of Mitozolomide (NSC 353451) a new imidazotetrazinone, against xenografts from human melanomas, sarcomas and lung and colon carcinomas, Cancer Res. 45:1778 (1985).PubMedGoogle Scholar
  17. 17.
    S. Gundersen, S. Aamdal and O. Fodstad, Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma, Phase II trial in patients with advanced disease, Br. J. Cancer 55:433 (1987).PubMedCrossRefGoogle Scholar
  18. 18.
    C.M.T. Horgan and M.J. Tisdale, Antitumour Imidazotetrazinones — IV. An investigation into the mechanism of antitumour activity of a novel and potent antitumour agent, mitozolomide (CCRG81010, M and B 39565, NSC 353451), Biochem. Pharmacol. 33:2185 (1984).PubMedCrossRefGoogle Scholar
  19. 19.
    N.W. Gibson, L.C. Erickson and J.A. Hickman, Effects of the antitumour agent 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one on the DNA of mouse L1210 cells. Cancer Res. 44:1767 (1984).PubMedGoogle Scholar
  20. 20.
    N.W. Gibson, J.A. Hickman and L.C. Erickson, DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, Cancer Res. 44:1772 (1984).PubMedGoogle Scholar
  21. 21.
    N.W. Gibson, J.A Hartley, D. Barnes and L.C. Erickson, Combined effects of streptozotocin and mitozolomide against four human cell lines of the Mer+ phenotype, Cancer Res. 46:4995 (1986).PubMedGoogle Scholar
  22. 22.
    M.J. Tisdale, Antitumour imidazotetrazines — XV, Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones, Biochem. Pharmacol. 36:457 (1987).PubMedCrossRefGoogle Scholar
  23. 23.
    M.J. Tisdale, Induction of haemoglobin synthesis in the human leukaemia cell line K562 by monomethyltriazenes and imidazotetrazinones, Biochem. Pharmacol. 34: 2077 (1985).PubMedCrossRefGoogle Scholar
  24. 24.
    M. Zucchetti, C.V. Catapano, S. Filippeschi, E. Erba and M. D’Incalci, Temozolomide induced differentiation of K562 leukaemia cells is not mediated by gene hypomethylation, Biochem. Pharmacol. 38:2069 (1989).PubMedCrossRefGoogle Scholar
  25. 25.
    M.J. Tisdale, Antitumour Imidazotetrazinones — X. Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one (CCRG 81045, M and B 39831, NSC 362856) on DNA methylation during induction of haemoglobin synthesis in human leukaemia cell line K562, Biochem. Pharmacol. 35:311 (1986).PubMedCrossRefGoogle Scholar
  26. 26.
    R.S. Wu, S. Hurst-Calderone and K.W. Kohn, Measurement of O6-alkyl-guanine-DNA alkyltransferase activity in human cells and tumor tissues by restriction endonuclease inhibition, Cancer Res. 47:6229 (1987).PubMedGoogle Scholar
  27. 27.
    M.J. Tisdale, Antitumour imidazotetrazinones and gene expression, Acta Oncologica 27:511 (1988).PubMedCrossRefGoogle Scholar
  28. 28.
    M.J. Tisdale, Antitumour imidazotetrazinones — XVIII. Modification of the level of 5-methylcytosine in DNA by 3-substituted imidazotetrazinones, Biochem. Pharmacol. 38:1097 (1989).PubMedCrossRefGoogle Scholar
  29. 29.
    M.C. Vogel, T. Papadopoulos, H.K. Müller-Hermelink, D. Drahovsky and G.P. Pfeifer, Intracellular distribution of DNA methyltransferase during the cell cycle, FEBS Lett. 236:9 (1988).PubMedCrossRefGoogle Scholar
  30. 30.
    C.V. Catapano, M. Broggini, E. Erba, M. Ponti, L. Mariani, L. Citti and M. D’Incalci, In vitro and in vivo methazolastone-induced DNA damage and repair in L1210 leukaemia sensitive and resistant to chloroethylnitrosoureas, Cancer Res. 47:4884 (1987).PubMedGoogle Scholar
  31. 31.
    V.L. Wilson, P.A. Jones and R.L. Momparier, Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2’-deoxycytidine as a possible mechanism of chemotherapeutic action, Cancer Res. 43:3493 (1983).PubMedGoogle Scholar
  32. 32.
    J. Vesley and A. Cihak, Incorporation of a potent antileukemic agent, 5-aza-2’-deoxycytidine into DNA of cells from leukemic mice, Cancer Res. 37:3684 (1977).Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • M. J. Tisdale
    • 1
  1. 1.Cancer Research Campaign Experimental Chemotherapy Group, Pharmaceutical Sciences InstituteAston UniversityBirminghamUK

Personalised recommendations